Tenax Therapeutics loses audit committee independence after director resignation; Nasdaq grants cure period

TENAX THERAPEUTICS, INC.

Director James Mitchum resigned from the Board and its Audit and Compensation Committees effective Sept 8, 2021, for personal reasons.
Resignation leaves the Audit Committee below the three independent members required by Nasdaq Listing Rule 5605(c)(2)(A).
Nasdaq granted a cure period ending at the next annual meeting or March 7, 2022, whichever is earlier.
Company has begun searching for a new independent director to serve on the Audit Committee.

item 3.01 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

James Mitchum

Director

TENX · TENAX THERAPEUTICS, INC.

Effective: 2021-09-08
Filed: September 14, 2021, 7:59 PM ET

On September 8, 2021, James Mitchum notified the Company that he is voluntarily resigning from the Board and its Audit and Compliance Committee and Compensation Committee, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Mitchum resigned as Director at TENAX THERAPEUTICS, INC..

Action: resigned
Role: Director

Exact text from the filing

On September 8, 2021, James Mitchum notified the Company that he is voluntarily resigning from the Board and its Audit and Compliance Committee and Compensation Committee, effective immediately.

View on SEC.gov

TENAX THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001654954-21-010080

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.